As of June 14, 2025, Lotus Pharmaceuticals Inc (LTUS) reports a ROE (Return on Equity) of 16.20%.
ROE (Return on Equity) measures how well a company generates profits from shareholders' investments, indicating equity efficiency.
Historical Trend of Lotus Pharmaceuticals Inc's ROE (Return on Equity)
Over recent years, Lotus Pharmaceuticals Inc's ROE (Return on Equity) has shown significant volatility. The table below summarizes the historical values:
| Date | ROE (Return on Equity) |
|---|---|
| 2010-12-31 | 16.20% |
| 2009-12-31 | 24.97% |
| 2008-12-31 | 28.34% |
| 2007-12-31 | 42.11% |
| 2006-12-31 | 35.10% |
This gradual decrease highlights how Lotus Pharmaceuticals Inc manages its efficiency in generating profits from shareholders' equity over time.
Comparing Lotus Pharmaceuticals Inc's ROE (Return on Equity) to Peers
To better understand Lotus Pharmaceuticals Inc's position, it's useful to compare its ROE (Return on Equity) against industry peers. Below are selected comparisons:
| Company | ROE (Return on Equity) |
|---|---|
| Lotus Pharmaceuticals Inc (LTUS) | 16.20% |
| Verrica Pharmaceuticals Inc (VRCA) | 776.66% |
| Aquestive Therapeutics Inc (AQST) | 73.37% |
| OptiNose Inc (OPTN) | 53.37% |
| BioDelivery Sciences International Inc (BDSI) | 45.18% |
| Strongbridge Biopharma plc (SBBP) | 28.19% |
Compared to its competitors, Lotus Pharmaceuticals Inc's ROE (Return on Equity) is among the highest compared to peers, suggesting efficient use of shareholder equity to generate profits.